

Poster Presentation

Open Access

Production of human α_1 proteinase inhibitor from *Aspergillus niger* Liat Chill¹, Loc B Trinh¹, Elena Karnaukhova², Yakir Ophir², Basil Golding² and Joseph Shiloach^{*1}

Address: ¹Biotechnology Unit, NIDDK, NIH, Bethesda, MD 28092, USA and ²Division of Hematology, CBER, FDA, Bethesda, MD 28095, USA

* Corresponding author

from The 4th Recombinant Protein Production Meeting: a comparative view on host physiology
Barcelona, Spain. 21–23 September 2006

Published: 10 October 2006

Microbial Cell Factories 2006, **5**(Suppl 1):P62 doi:10.1186/1475-2859-5-S1-P62

© 2006 Chill et al; licensee BioMed Central Ltd.

Background

α_1 proteinase inhibitor (α_1 PI) belongs to the serin protease inhibitor (serpin) family; it is responsible for 90% of the trypsin inhibitory capacity of human plasma. Its primary physiological role is to inhibit neutrophil elastase that degrades elastin, collagen and proteoglycan and can cause extensive lung damage. α_1 PI deficiency can result in lung emphysema in adults, liver disease in children and is also associated with cystic fibrosis, arthritis and other malignant conditions [1-3]. Human plasma-derived α_1 PI is a licensed product used for replacement therapy. Although viral inactivation measures are taken, products derived from human plasma carry the risk of contamination with blood-borne pathogens, and therefore recombinant is an attractive alternative.

α_1 PI exhibits a molecular mass of approximately 52 kD, has 394 amino acids, a single cysteine residue and three carbohydrate attachment sites at asparagine residues 46, 83 and 247 [4,5]. Significant research effort was directed to produce recombinant human α_1 PI in *E. coli* [6], yeast [7], transgenic mice and sheep as well as plant cells [3]. *E. coli* produced an unglycosylated product, the yeast produced incorrect glycosylation and the transgenic animals pose the same threats as plasma derived product.

Results

Human α_1 PI was cloned and expressed in *Aspergillus niger*, filamentous fungus that can grow in defined media and had the ability to perform glycosylation. Submerged culture conditions were established: using starch as carbon source, 30% dissolved oxygen concentration, pH 7.0 and

28°C; 10 mg per liter of active α_1 PI were secreted to the growth media in 40 hours. Controlling the protein proteolysis was found to be an important factor in the production from the fungus. The effect of carbon sources and growth conditions on the production and stability of the protein will be presented and evaluated.

References

1. Mattes E, Matthiessen HP, Turecek PL, Schwarz HP: **Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity.** *Vox Sang* 2001, **81**:29-36.
2. Travis J, Owen M, George P, Carrell R, Rosenberg S, Hallewell RA, Barr PJ: **Isolation and properties of recombinant DNA produced variants of Human α_1 -proteinase inhibitor.** *J Biol Chem* 1985, **260**:4384-4389.
3. Huang J, Sutliff TD, Wu L, Nandi S, Bengel K, Terashima M, Ralston AH, Drohan W, Huang N, Rodriguez RL: **Expression and purification of functional human α_1 -antitrypsin from cultured plant cells.** *Biotechnol Prog* 2001, **17**:126-133.
4. Chen SX, Hammond DJ, Klos AM, Wood WD, Wydick JE, Lebing WR: **Chromatographic purification of human α_1 proteinase inhibitor from dissolved Cohn fraction IV-1 paste.** *J Chromatogr A* 1998, **800**:207-218.
5. Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell R: **Structure and variation of human α_1 -antitrypsin.** *Nature* 298:329-334.
6. Courtney M, Buchwalder A, Tessier L, Jaye M, Benavente A, Balland A, Kohli V, Lathe R, Tolstoshev P, Lecocq J: **High level production of biologically active α_1 -antitrypsin in *Escherichia coli*.** *Proc Natl Acad Sci USA* 1984, **81**:669-673.
7. Kwon KS, Song M, Yu MH: **Purification and characterization of α_1 -antitrypsin secreted by recombinant yeast *Saccharomyces diastaticus*.** *J Biotechnol* 1995, **42**:19.